Bayer Schering Pharma has obtained access to five cancer-related targets from Celera for therapeutic development and in vivo diagnostic imaging. Celera retains in vitro diagnostic rights and will be able to develop and commercialize related companion diagnostics for candidates arising from Bayer Schering Pharma’s program.
The therapeutic targets licensed under this exclusive agreement are reportedly over expressed on the surface of several different tumor cell types. They were found with Celera’s proteomics discovery platform.
Bayer Schering Pharma will pay Celera an up-front fee, and additional payments are due upon achievement of certain development and commercial milestones. Upon commercialization of a product, Celera is entitled to royalties based on net sales.
Bayer Pays $4M Upfront to Use ImmunoGen’s Technology for a Solid Tumor Target (Oct. 21, 2008)
Bayer Pays Ardea $35M for Its Anticancer MEK Inhibitors (Apr. 28, 2009)
Merck & Co. In-Licenses Cancer Targets from Celera to Develop RNAi Drugs (Apr. 10, 2008)
Celera Licenses Oncology-Related Discoveries to LabCorp (Apr. 25, 2007)